Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older

Elizabeth F Juniper, Klas Svensson, Ann-Christin Mörk, Elisabeth Ståhl, Elizabeth F Juniper, Klas Svensson, Ann-Christin Mörk, Elisabeth Ståhl

Abstract

Background: The age limit for some adult asthma clinical trials has recently been lowered to 12 years. In this study we have made minor modifications to the standardised version of the adult Asthma Quality of Life Questionnaire (AQLQ(S)) to make it valid for patients 12 years and older (AQLQ12+).

Methods: We have used two clinical trial databases, in which the AQLQ12+ was used, to compare the measurement properties of the questionnaire in patients 12-17 years and patients 18 years and older. A total of 2433 patients (12-75 years), with current asthma and with data that could be evaluated both at randomisation and end of treatment, were included.

Results: The analysis showed that internal consistency, responsiveness and correlations with other clinical indices were very similar in patients 12-17 years and patients 18 years and older.

Conclusion: The measurement properties of the AQLQ12+ are similar in adolescents and adults and therefore the instrument is valid for use in adult studies which include children 12 years and older.

References

    1. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83.
    1. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5:35–46. doi: 10.1007/BF00435967.
    1. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999;115:1265–1270. doi: 10.1378/chest.115.5.1265.
    1. Scicchitano R, Aalbers R, Ukena D, Manjara A, Fouquert L, Centanni S, Boulet LP, Naya IP, Hultquist C. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20:1403–1418. doi: 10.1185/030079904X2051.
    1. Morice AH, Osmanliev D, Arheden L, Beckman O. Therapeutic equivalence of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler(R) in adolescents and adults with asthma. J Allergy Clin Immunol. 2005;115:S2. doi: 10.1016/j.jaci.2004.12.025. Abs 8.
    1. Morice AH, Kukova Z, Arheden L, Beckman O. The novel budesonide/formoterol pMDI is therapeutically equivalent to budesonide/formoterol Turbuhaler(R) in children with asthma. J Allergy Clin Immunol. 2005;115:S209. doi: 10.1016/j.jaci.2004.12.846. Abs 833.
    1. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:832–838.
    1. Sanjuas C, Alonso J, Sanchis J, Casan P, Broquetas JM, Ferrie PJ, Juniper EF, Anto JM. The quality of life questionnaire with asthma patients; the Spanish version of the Asthma Quality of Life Questionnaire. Arch Bronconeumol. 1995;31:219–226.
    1. Leidy NK, Coughlin C. Psychometric performance of the Asthma Quality of Life Questionnaire in a US sample. Qual Life Res. 1998;7:127–134. doi: 10.1023/A:1008853325724.
    1. Rutten-van Molken MPMH, Clusters F, Van Doorslaer EKA, Jansen CCM, Heurman L, Maesen FPV, Smeets JJ, Bommer AM, Raaijmakers JAM. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J. 1995;8:888–898.
    1. Juniper EF, Norman GR, Cox FM, Roberts JN. Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma. Eur Respir J. 2001;18:38–44. doi: 10.1183/09031936.01.00088301.
    1. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol. 1994;47:81–87. doi: 10.1016/0895-4356(94)90036-1.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi